Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) EBIT (2016 - 2025)

Haemonetics has reported EBIT over the past 17 years, most recently at $67.4 million for Q4 2025.

  • Quarterly results put EBIT at $67.4 million for Q4 2025, up 14.17% from a year ago — trailing twelve months through Dec 2025 was $251.1 million (up 39.17% YoY), and the annual figure for FY2025 was $221.8 million, up 34.53%.
  • EBIT for Q4 2025 was $67.4 million at Haemonetics, up from $58.5 million in the prior quarter.
  • Over the last five years, EBIT for HAE hit a ceiling of $71.3 million in Q1 2025 and a floor of -$21.2 million in Q2 2021.
  • Median EBIT over the past 5 years was $41.5 million (2022), compared with a mean of $39.1 million.
  • Biggest five-year swings in EBIT: plummeted 181.42% in 2021 and later surged 2113.45% in 2022.
  • Haemonetics' EBIT stood at $24.5 million in 2021, then soared by 76.58% to $43.3 million in 2022, then rose by 6.24% to $46.0 million in 2023, then rose by 28.39% to $59.0 million in 2024, then rose by 14.17% to $67.4 million in 2025.
  • The last three reported values for EBIT were $67.4 million (Q4 2025), $58.5 million (Q3 2025), and $53.9 million (Q2 2025) per Business Quant data.